Celltrion Sees Double-Digit Growth In Sales And Profit

As Company’s Biosimilars Strategy Continues To Deliver

11 Mar 2021

• By Akriti Seth

South Korea’s Celltrion saw a double-digit jump in sales and operating profit in 2020 based on continued growth for its leading biosimilars. Meanwhile, the company is pursuing its strategy of developing at least one biosimilar annually.

South Korea Money — South Korea’s Celltrion sees YoY jump in sales on the back of “continued growth of major products” • Source: Shutterstock

Celltrion Sees Double-Digit Growth In Sales And Profit

As Company’s Biosimilars Strategy Continues To Deliver

More from Biosimilars

More from Products